Fosun Kite

Company

Last mentioned: Mar 24, 2026

Timeline

  1. Annual Results

    Official release of 2025 financial performance data to global markets.

  2. Global Partnership

    Strategic agreement signed for the distribution of biosimilars in emerging markets.

  3. CAR-T Milestone

    Fosun Kite announces expanded indications for Yi Kai Da CAR-T therapy.

  4. Regional Launch

    Serplulimab receives regulatory approval in additional Southeast Asian markets.

Stories mentioning Fosun Kite 1

earnings Neutral

Fosun Pharma 2025 Results Highlight Innovation Pivot and Global Expansion

Fosun Pharma reported robust 2025 financial results, driven by a record contribution from innovative drugs and successful expansion into Southeast Asian markets. The company's strategic focus on high-barrier biologics and R&D has solidified its transition from a generic-focused manufacturer to a global innovation leader.

2 sources